epidem
infect
continu
unab
worldwid
problem
absenc
effect
vaccin
highli
activ
antiretrovir
therapi
haart
use
mainli
reversetranscriptas
proteas
inhibitor
dramat
decreas
morbid
mortal
among
peopl
live
sever
entri
inhibitor
includ
fusion
inhibitor
enfuvirtid
fuzeon
coreceptor
antagonist
maraviroc
selzentri
also
approv
us
fda
use
especi
patient
fail
respond
haart
howev
success
treatment
frequent
limit
seriou
advers
effect
emerg
drugresist
mutant
thu
urgent
need
develop
new
class
inhibitor
differ
mechan
action
combin
exist
inhibitor
could
exhibit
increas
antivir
potenc
breadth
durabl
viral
resist
class
natur
inhibitor
entri
neutral
monoclon
antibodi
nab
potent
gener
specif
safer
small
molecul
drug
thu
extens
explor
candid
therapeut
prophylact
howev
evolv
varieti
strategi
escap
neutral
antibodi
gener
human
immun
system
extrem
variabl
envelop
glycoprotein
env
steric
occlus
conserv
neutral
epitop
inde
sever
human
broadli
nab
includ
highli
effect
infect
vitro
confer
steril
protect
anim
model
administr
human
result
modest
antivir
effect
disappoint
result
contrast
clinic
benefit
provid
current
approv
therapeut
antibodi
diseas
sinc
new
human
broadli
nab
identifi
use
novel
select
approach
highthroughput
b
cell
sort
function
screen
antibodi
includ
target
site
direct
conserv
region
variabl
loop
preferenti
express
trimer
env
seri
pgt
antibodi
bind
variou
novel
epitop
specif
membraneproxim
extern
region
mper
averag
potent
broadli
neutral
vitro
therefor
could
promis
prevent
therapi
date
howev
much
data
vivo
experi
could
prove
possibl
antibodi
fragment
small
size
could
effect
natur
occur
fulllength
antibodi
could
easili
gain
access
highli
guard
conserv
structur
env
line
possibl
find
fab
scfv
format
antibodi
target
coreceptorbind
site
gener
superior
igg
format
neutral
therefor
hypothes
decreas
size
antibodi
fragment
smallest
independ
fold
singl
antibodi
domain
maintain
high
bind
affin
could
lead
except
potent
broadli
crossreact
neutral
pan
larg
highli
diversifi
librari
human
vh
domain
sequenti
two
env
differ
isol
identifi
first
report
human
vh
show
potent
inhibitori
activ
genet
divers
isol
also
activ
virus
resist
ibalizumab
clinic
test
broadli
neutral
mab
bnmab
direct
mainli
second
extracellular
domain
http
human
mice
model
affinitymatur
version
provid
steril
protect
four
six
anim
intrasplen
challeng
hightit
extens
infect
detect
four
control
anim
http
interestingli
abl
enhanc
bind
broadli
nab
recombin
suggest
fusion
protein
could
novel
type
candid
vaccin
immunogen
possibl
better
alon
studi
fine
character
epitop
combin
three
power
approach
includ
mimotopebas
comput
predict
molecular
dock
site
mutagenesi
result
provid
import
inform
understand
mechan
inhibit
explor
structur
function
env
also
help
develop
novel
class
potenti
promis
entri
inhibitor
compon
vaccin
immunogen
previou
studi
reveal
target
highli
conserv
structur
may
overlap
coreceptorbind
site
howev
bind
motif
residu
character
number
studi
demonstr
mimotopebas
predict
serv
ideal
approach
map
conform
epitop
given
antibodi
sought
select
mimotop
random
peptid
phage
display
librari
three
round
biopan
total
posit
phage
clone
isol
dna
sequenc
insert
identifi
differ
peptid
mimotop
fig
notabl
one
peptid
vplwwissfmpi
predomin
select
howev
could
find
appar
consensu
sequenc
significantli
homolog
motif
use
deduc
bind
site
residu
suggest
confirmationdepend
natur
epitop
mostli
exposedform
bind
base
select
mimotop
predict
potenti
bind
residu
comput
algorithm
mapitop
power
tool
map
antibodi
epitop
program
rank
cluster
identifi
better
candid
epitop
compar
point
quantum
jump
defin
q
point
signific
increas
number
amino
acid
beyond
q
point
may
result
merg
adjac
cluster
recruit
peripher
underli
irrelev
amino
acid
lead
sharp
increas
number
amino
acid
associ
given
valu
select
peptid
analyz
rang
valu
one
cluster
predict
sinc
valu
would
show
sharp
rise
residu
number
cluster
cluster
may
adequ
amount
residu
q
point
peptid
librari
conduct
point
st
fig
total
residu
cluster
predict
primarili
locat
conserv
region
fig
includ
one
except
local
within
loop
appar
sever
amino
acid
stretch
overlap
neighbor
receptor
coreceptorbind
site
conceiv
small
size
vhbase
might
better
access
resid
compar
antibodi
pair
vh
vl
local
key
residu
bind
site
target
chose
perform
molecular
dock
studi
interact
blast
search
analysi
reveal
amino
acid
sequenc
similar
three
pdb
entri
highest
similar
although
diminish
similar
cdr
base
crystal
structur
model
develop
help
model
program
suit
discoveri
studio
refin
use
modloop
program
fig
qualiti
structur
assess
ramachandran
plot
fig
amino
acid
residu
found
allow
region
profil
verifi
score
final
vh
model
higher
verifi
expect
high
score
confirm
reliabl
model
structur
fig
gain
insight
interact
dock
model
crystal
structur
use
zdock
program
top
complex
obtain
group
cluster
accord
interact
model
complex
zdock
score
refin
rerank
rdock
program
fig
final
rdock
energi
analysi
indic
pose
belong
cluster
lowest
erdock
score
fig
erdock
score
pose
similar
pose
shown
fig
three
pose
contain
three
amino
acid
segment
correspond
drastic
differ
domain
suggest
zdock
may
provid
altern
confound
outcom
observ
amino
acid
stretch
motif
pose
relat
receptor
coreceptor
bind
share
common
residu
predict
mapitop
contrast
residu
pose
includ
bind
site
receptor
antibodi
impli
might
particip
interact
therefor
select
pose
dock
character
structur
fig
first
segment
pose
overlap
region
stem
third
segment
locat
within
hairpin
region
segment
involv
format
bridg
sheet
outer
inner
domain
critic
bind
coreceptor
antibodi
particularli
second
segment
within
excurs
portion
bind
loop
nine
residu
three
conserv
domain
identifi
mimotopebas
predict
molecular
dock
two
stem
domain
design
site
five
domain
site
anoth
two
domain
site
although
three
discontinu
site
wide
distribut
linear
sequenc
close
proxim
structur
fig
therefor
analyz
potenti
import
residu
sitedirect
mutagenesi
alanin
scan
three
residu
map
mapitop
alon
also
includ
shown
fig
recombin
carri
specif
point
mutat
bound
solubl
polyclon
antihiv
antibodi
hivig
strength
compar
wildtyp
indic
correctli
fold
next
test
protein
bind
absenc
presenc
weakli
react
wildtyp
mutat
without
data
shown
presenc
bound
wildtyp
substitut
compar
fig
contrast
mutat
six
residu
includ
four
residu
site
two
residu
site
larg
reduc
reactiv
suggest
residu
play
critic
role
interact
presenc
interact
defin
six
residu
determin
program
protein
interfac
analysi
dock
model
show
cdr
interact
form
two
hydrogen
bond
number
nonbond
contact
fig
residu
locat
mainli
two
domain
bridg
sheet
loop
nonbond
interact
mostli
caus
residu
creat
two
hydrogen
bond
carboxyl
oxygen
atom
distanc
distanc
respect
work
aim
map
fine
epitop
highli
potent
human
antibodi
domainbas
inhibitor
entri
target
env
achiev
goal
integr
three
power
approach
includ
mimotopebas
comput
predict
molecular
dock
sitedirect
mutagenesi
three
conserv
region
compris
six
key
residu
site
site
site
identifi
might
interact
overlap
close
proxim
coreceptorbind
site
result
provid
insight
mechan
potent
broad
inhibit
infect
help
futur
develop
novel
class
inhibitor
entri
cell
entri
mediat
trimer
env
complex
compos
surfac
subunit
transmembran
subunit
bind
cell
receptor
induc
larg
conform
chang
result
exposur
andor
format
coreceptorbind
site
enabl
bind
coreceptor
either
subsequ
fusion
machineri
origin
shelter
activ
thu
bring
viral
cellular
membran
close
proxim
fusion
entri
step
offer
attract
target
antivir
agent
includ
antibodi
previou
studi
demonstr
coreceptorbind
site
target
antibodi
possess
highli
potent
broad
inhibitori
activ
compar
antibodi
block
bind
antibodi
sever
antibodi
target
coreceptorbind
site
antibodi
gener
less
effect
neutral
interestingli
neutral
invers
correl
antibodi
size
exampl
fab
size
kda
neutral
virus
gener
better
igg
format
kda
scfv
kda
could
potent
fab
format
propos
sizedepend
neutral
could
due
steric
restrict
antibodi
access
epitop
avail
space
viru
target
cell
surfac
bind
enough
accommod
whole
antibodi
molecul
therefor
conceiv
smallest
independ
fold
antibodi
domain
kda
exhibit
potent
broad
neutral
activ
target
hidden
conserv
structur
access
larger
antibodi
agreement
hypothesi
sever
singl
heavi
chain
variabl
domain
refer
vhh
success
isol
llama
immun
character
potent
entri
inhibitor
interf
viru
bind
first
report
engin
antibodi
domain
ead
size
kda
possess
extraordinarili
potent
activ
inhibit
genet
divers
isol
thu
show
great
potenti
overcom
disadvantag
larger
antibodi
base
significantli
increas
reactiv
upon
bind
propos
might
bind
conserv
structur
inde
studi
local
bind
residu
near
coreceptor
bind
site
appar
constitut
three
conserv
motif
resid
respect
stem
site
site
site
region
sitedirect
mutagenesi
verifi
total
six
residu
two
site
primarili
involv
format
epitop
structur
residu
locat
bridg
sheet
region
residu
within
loop
excurs
notabl
character
residu
highli
conserv
among
isol
explain
broadspectrum
hivneutr
activ
molecular
architectur
env
spike
associ
conform
chang
upon
bind
antibodi
fine
analyz
use
cryoelectron
tomographi
reveal
three
distinct
quaternari
conform
trimer
env
close
conform
found
trimer
env
unligand
bound
antibodi
character
close
posit
adjac
loop
apex
spike
partial
open
conform
observ
env
bound
cdb
antibodi
defin
slight
outward
rotat
displac
monom
respect
central
axi
spike
third
open
env
structur
observ
upon
bind
solubl
antibodi
featur
quaternari
conform
larg
rearrang
recent
determin
structur
complex
trimer
env
nativ
virion
cryoelectron
tomographi
show
bind
env
result
open
quaternari
conform
similar
seen
bind
solubl
structur
env
display
area
extra
densiti
apex
spike
near
coreceptor
bind
site
footprint
bind
near
base
loop
locat
similar
antibodi
due
low
resolut
cryoelectronbas
structur
imposs
discern
bind
residu
specif
antibodi
interestingli
studi
discov
target
face
bridg
sheet
critic
bind
fig
wherea
epitop
resid
opposit
face
bridg
sheet
howev
surpris
identif
receptor
residu
includ
loop
partial
epitop
inde
previou
studi
show
could
react
sever
protein
absenc
molecul
deriv
differ
isol
interestingli
studi
also
demonstr
singl
gln
q
glu
e
mutat
region
could
abolish
reactiv
verifi
strongli
bind
protein
depend
addit
data
shown
therefor
receptor
coreceptorbind
residu
may
involv
format
epitop
taken
togeth
result
provid
structur
basi
underli
bind
neutral
activ
crystal
structur
complex
absenc
andor
presenc
solubl
would
help
character
epitop
unfortun
success
far
grow
good
qualiti
crystal
complex
flagtag
human
domain
antibodi
express
e
coli
describ
previous
brief
bacteri
pellet
collect
centrifug
g
resuspend
pb
ph
contain
millionunit
polymixin
b
sigmaaldrich
min
incub
rotat
rpm
room
temperatur
centrifug
g
min
supernat
use
purif
immobil
metal
ion
affin
chromatographi
use
ninta
resin
qiagen
valencia
ca
accord
manufactur
protocol
random
phage
display
librari
wherein
display
peptid
fuse
n
terminu
giii
protein
purchas
new
england
biolab
beverli
complex
librari
estim
suffici
encod
peptid
sequenc
affin
select
phage
clone
librari
perform
accord
manufactur
instruct
briefli
plate
costar
ny
usa
coat
buffer
ph
overnight
coat
well
block
bsa
buffer
h
wash
time
tbst
phage
librari
ad
coat
well
incub
room
temperatur
h
well
extens
wash
tbst
time
bound
phage
elut
glycinehcl
ph
contain
mgml
bsa
neutral
trishcl
ph
elut
phage
amplifi
infect
logphag
e
coli
concentr
polyethylen
glycol
peg
precipit
phage
titter
submit
second
round
select
round
select
select
phage
clone
identifi
singlestrand
dna
sequenc
encod
peptid
sequenc
mimotop
deduc
verif
posit
phage
clone
indirect
phage
elisa
perform
briefli
microtit
plate
coat
ngwell
block
bsa
affinityselect
phage
first
amplifi
ml
cultur
ad
ul
dilut
cultur
supernat
coat
well
plate
incub
h
room
temperatur
wash
three
time
tbst
tween
hrpconjug
murin
antibodi
sigma
ad
well
incub
h
well
extens
wash
tbst
react
tmb
substrat
sigma
absorb
nm
measur
elisa
reader
biorad
potenti
bind
residu
comput
predict
mapitop
algorithm
valid
effici
map
conformationdepend
bind
site
epitop
base
affinityselect
mimotop
number
studi
principl
algorithm
mapitop
base
assumpt
epitop
separ
sever
amino
acid
pair
aap
contribut
bind
antibodi
entir
set
peptid
enrich
aap
mimic
genuin
epitop
pair
residu
significantli
overrepres
panel
peptid
identifi
comparison
expect
frequenc
mapitop
search
patch
surfac
enrich
pair
result
patch
present
protein
structur
number
standard
deviat
random
given
pair
defin
statist
threshold
st
frequent
aap
identifi
algorithm
seek
pair
select
distanc
valu
surfac
antigen
attempt
link
cluster
discoveri
studio
ds
accelri
softwar
inc
san
diego
ca
model
block
use
construct
homolog
model
heavi
chain
coordin
antibodi
pdb
code
use
templat
structur
align
produc
homolog
model
cdr
loop
vh
domain
model
identifi
antibodi
databas
reconstruct
use
model
antibodi
loop
protocol
subject
loop
refin
protocol
ds
final
vh
model
valid
use
ramachandran
plot
verifi
protein
protocol
proteinligand
dock
structur
pdb
code
retriev
pdb
initi
receptor
molecul
ds
tool
protein
prepar
possibl
torsion
angl
ligand
molecul
set
rotat
freeli
flexibl
molecular
dock
vh
onto
model
accomplish
use
zdock
protocol
ds
high
predict
accuraci
gener
algorithm
ga
paramet
ligand
ten
ligand
pose
gener
dock
experi
evalu
zdock
score
function
take
account
factor
hbond
energi
van
der
waal
energi
ligand
torsion
strain
ligand
pose
zdock
score
refin
analyz
use
rdock
ds
top
rank
ligand
pose
use
studi
molecular
interact
analyz
use
program
protein
interfac
analysi
vector
express
first
construct
pcr
clone
briefli
prime
start
dna
polymeras
takara
dalian
china
use
extend
pair
mutat
primer
introduc
stop
codon
uag
end
sequenc
use
plasmid
pcmvenv
templat
pcr
product
digest
dpni
neb
beverli
remov
methyl
parent
dna
dna
contain
desir
mutat
transform
e
coli
follow
plate
select
lb
plate
ampicillin
panel
site
mutat
correspond
predict
residu
gener
base
vector
templat
similarli
mutat
verifi
dna
sequenc
protein
express
confirm
westernblot
analyz
bind
activ
wildtyp
mutat
cell
transfect
specif
plasmid
cell
cultiv
h
optimdmem
medium
cultur
supernat
contain
express
protein
collect
elisa
assay
brief
microtit
well
coat
cultur
supernat
overnight
block
h
bsa
pb
follow
five
wash
pbst
first
reactiv
solubl
hivig
test
assess
bind
capac
wildtyp
mutat
reactiv
test
presenc
absenc
reaction
place
overnight
three
wash
well
incub
either
mous
antihi
tag
mab
mbl
woburn
mous
antiflag
tag
mab
mbl
woburn
goat
antihuman
igg
polyclon
antibodi
hivig
well
wash
time
pbst
tmb
substrat
sigma
st
loui
mo
usa
ad
absorb
measur
nm
